Ongentys (opicapone) approved for treatment of Parkinson's disease

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Ongentys (opicapone) has been licensed for use as adjunctive therapy to levodopa/DOPA decarboxylase inhibitors (DDCI) preparations in adults with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Opicapone is a third-generation selective ...